Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019

Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019

Objective: To explore the clinical value of immune-inflammatory markers to assess the severity of coronavirus disease 2019 (COVID-19). Methods: 127 consecutive hospitalized patients with confirmed COVID-19 were enrolled in this study, and classified into non-severe and severe groups. Demographics, s...

Full description

Bibliographic Details
Main Authors:	Zhe Zhu, Ting Cai, Lingyan Fan, Kehong Lou, Xin Hua, Zuoan Huang, Guosheng Gao
Format:	Article
Language:	English
Published:	Elsevier 2020-06-01
Series:	International Journal of Infectious Diseases
Subjects:	COVID-19 SARS-CoV-2 Immune-inflammatory parameters Cytokine storm IL-6
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971220302575

Similar Items

Nucleocapsid and Spike Proteins of the Coronavirus SARS-CoV-2 Induce <i>IL6</i> in Monocytes and Macrophages—Potential Implications for Cytokine Storm Syndrome
by: Iwona Karwaciak, et al.
Published: (2021-01-01)

Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019
by: Feng Gao, et al.
Published: (2021-03-01)

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors
by: Huan Han, et al.
Published: (2020-01-01)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
by: Corrado Pelaia, et al.
Published: (2021-03-01)

The Immune Response and Immunopathology of COVID-19
by: Esmaeil Mortaz, et al.
Published: (2020-08-01)

Evolution Toward Severe Covid-19 From Biological Monitoring to Therapeutic Considerations
by: Julien Carvelli, et al.
Published: (2020-12-01)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
by: Daria Fomina, et al.
Published: (2020-10-01)

Risk Factors Associated with the Clinical Outcomes of COVID-19 and Its Variants in the Context of Cytokine Storm and Therapeutics/Vaccine Development Challenges
by: John Hanna, et al.
Published: (2021-08-01)

Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review
by: Faryal Farooqi, et al.
Published: (2020-07-01)

Present and future treatment strategies for coronavirus disease 2019
by: Engy Elekhnawy, et al.
Published: (2021-04-01)

Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome
by: Shi-hui Lin, et al.
Published: (2020-12-01)

Simple prognostic factors and change of inflammatory markers in patients with severe coronavirus disease 2019: a single‐center observational study
by: Hisaya Domi, et al.
Published: (2021-01-01)

Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis
by: Adriana Albini, et al.
Published: (2021-09-01)

Demographic and clinical factors affecting serum IL-6, and its correlation with the severity, and mortality of COVID-19
by: Wael Hafez
Published: (2022-12-01)

Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications
by: Alessandro Allegra, et al.
Published: (2020-07-01)

Inosine: A broad-spectrum anti-inflammatory against SARS-CoV-2 infection-induced acute lung injury via suppressing TBK1 phosphorylation
by: Ningning Wang, et al.
Published: (2023-01-01)

Paradigm of immune dysregulation in coronavirus disease-2019 infection
by: Om Saswat Sahoo, et al.
Published: (2024-01-01)

The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019
by: Tao Liu, et al.
Published: (2020-07-01)

SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody
by: Collin Jugler, et al.
Published: (2021-11-01)

Why tocilizumab could be an effective treatment for severe COVID-19?
by: Binqing Fu, et al.
Published: (2020-04-01)

IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6
by: E. L. Nasonov
Published: (2020-06-01)

Prompt Reduction in CRP, IL-6, IFN-γ, IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19
by: Shoji Hashimoto, et al.
Published: (2021-09-01)

Efficacy of Tocilizumab in Patients with COVID-19
by: Ahmad Alikhani, et al.
Published: (2022-12-01)

The COVID-19 Cytokine Storm; What We Know So Far
by: Dina Ragab, et al.
Published: (2020-06-01)

A “Window of Therapeutic Opportunity” for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019
by: Ludovico De Stefano, et al.
Published: (2020-10-01)

COVID-19: Immunopathogenesis
by: Deniz MAVİ, et al.
Published: (2020-06-01)

The growth factor/cytokine midkine may participate in cytokine storm and contribute to the pathogenesis of severe acute respiratory syndrome coronavirus 2-infected patients
by: Sema Ketenci, et al.
Published: (2021-09-01)

Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study
by: Seyed Mehran Marashian, et al.
Published: (2022-07-01)

Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury
by: Xianyang Chen, et al.
Published: (2020-08-01)

Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?
by: Leland Shapiro, et al.
Published: (2023-10-01)

IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis
by: Browning L, et al.
Published: (2018-12-01)

SOLVx therapeutics vaccine – Activate T-cell immunity using broad surveillance epitope strategy against mutant strains SARS-COV2
by: Md Shamsuddin Sultan Khan, et al.
Published: (2022-08-01)

The dual sides of interferon induction in COVID-19 treatment
by: Sadra Nadimi Parashkouhi, et al.
Published: (2021-03-01)

Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review
by: David Banji, et al.
Published: (2021-03-01)

A Retrospective Assessment of Laboratory Findings and Cytokine Markers in Severe SARS-CoV-2 Infection among Patients of Roma Population
by: Alexandra Mocanu, et al.
Published: (2022-11-01)

On the role of bacterial metalloproteases in COVID-19 associated cytokine storm
by: László Földvári-Nagy, et al.
Published: (2021-01-01)

Clinical spectrum and prognostic markers of multi-system inflammatory syndrome in children hospitalised in Northern India
by: Areesha Alam, et al.
Published: (2023-09-01)

Inflammatory cytokine and plasma C-reactive protein response to ketoacidosis in adults with type 1 diabetes: Egyptian multicenter study
by: Ghada A. Mohamed, et al.
Published: (2020-12-01)

A comprehensive review and meta-analysis of the relationships between interleukin-7 levels and COVID-19 severity
by: Michal MATUSZEWSKI, et al.
Published: (2023-03-01)

Mutations in SARS-CoV-2 variant nsp6 enhance type-I interferon antagonism
by: Cody J. Bills, et al.
Published: (2023-12-01)